The Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) drugs in development market research report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued products.

GlobalData tracks 50 drugs in development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) by 44 companies/universities/institutes. The top development phase for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) is preclinical with 23 drugs in that stage. The Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline has 49 drugs in development by companies and one by universities/ institutes. Some of the companies in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline products market are: Beijing Tide Pharmaceutical, Foresee Pharmaceuticals and G&P Bioscience.

The key targets in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline products market include Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1), Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF), and Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1).

The key mechanisms of action in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline product include Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1) Agonist with three drugs in Phase II. The Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline products include 13 routes of administration with the top ROA being Intravenous and 12 key molecule types in the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline products market including Small Molecule, and Cell Therapy.

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) overview

Peripheral arterial disease (PAD) and peripheral vascular disease (PVD) refer to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh, or calf muscles after activity, such as walking or climbing stairs (intermittent claudication); leg numbness or weakness; coldness in lower leg or foot, especially when compared with the other side; sores on toes, feet, or legs that won’t heal; slower growth of toenails; and erectile dysfunction in men.

For a complete picture of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.